1. Home
  2. LYEL

as 03-28-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Founded: 2018 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 207.7M IPO Year: 2021
Target Price: $1.00 AVG Volume (30 days): 878.9K
Analyst Decision: Sell Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.31 EPS Growth: N/A
52 Week Low/High: $0.48 - $3.15 Next Earning Date: 03-11-2025
Revenue: $61,000 Revenue Growth: -53.08%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

LYEL Daily Stock ML Predictions

Stock Insider Trading Activity of Lyell Immunopharma Inc. (LYEL)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Ramachandra Sumant LYEL Director Mar 21 '25 Buy $0.58 200,000 $115,220.00 200,000
Newton Charles W. LYEL Chief Financial Officer Mar 17 '25 Buy $0.56 200,000 $111,620.00 200,000
Klausner Richard LYEL Director Mar 14 '25 Buy $0.60 158,000 $94,942.20 843,365

Share on Social Networks: